Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca

Rhea-AI Summary

Pinetree Therapeutics announced AstraZeneca (LSE/STO/NYSE: AZN) has exercised its option to obtain an exclusive global license to develop and commercialize PTX-299, a bispecific antibody degrader targeting EGFR.

The option exercise triggers a $25 million option-closing payment to Pinetree and makes AstraZeneca responsible for global development and commercialization; the deal includes future development, regulatory, and commercial milestones plus tiered royalties, with total potential value exceeding $500 million.

Positive

• $25M option-closing payment to Pinetree
• AstraZeneca assumes global development and commercialization responsibility
• Agreement includes future milestone payments and tiered royalties
• Total potential deal value exceeds $500M

Negative

• Pinetree cedes development control to AstraZeneca
• Future payments are milestone-dependent and not guaranteed

News Market Reaction – AZN

+1.17%

+1.17% Session close to close

In the Apr 30 session, AZN gained 1.17%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights AstraZeneca’s continued expansion in oncology through external innovati...

Analysis

This announcement highlights AstraZeneca’s continued expansion in oncology through external innovation, adding an EGFR-targeting degrader program licensed from Pinetree. It follows recent FDA approvals and Phase III successes across respiratory and oncology, reinforcing a strategy of broad late-stage and early-platform exposure. Investors may track future updates on clinical progression, regulatory milestones, and how this program complements existing EGFR and targeted therapy assets within the pipeline.

Key Figures

Option payment: $25 million Deal potential value: Exceeds $500 million

2 metrics

Option payment $25 million Option exercise payment from AstraZeneca to Pinetree

Deal potential value Exceeds $500 million Total potential value including milestones and royalties

Historical Context

5 past events · Latest: Apr 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Drug approval	Positive	-0.4%	US FDA approval of BREZTRI Aerosphere for asthma triple therapy.
Apr 27	Drug approval	Positive	-1.2%	US approval of SAPHNELO autoinjector for self-administered SLE treatment.
Apr 20	Clinical trial result	Positive	-2.0%	Tozorakimab met primary endpoint in Phase III MIRANDA COPD trial.
Apr 02	Clinical trial result	Positive	+1.4%	IMFINZI + IMJUDO combo improved PFS in early liver cancer trial.
Mar 27	Clinical trial result	Positive	+2.7%	Tozorakimab met primary endpoints in OBERON and TITANIA COPD trials.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and regulatory updates often saw mixed or negative next-day price reactions, indicating a history of good news not always translating into immediate gains.

Recent Company History

Over the last month, AZN reported multiple positive developments, including FDA approvals for BREZTRI and SAPHNELO Pen and several Phase III successes such as tozorakimab COPD trials and the EMERALD-3 liver cancer study. Despite these favorable updates, three of the last five events were followed by negative 24-hour moves, while two saw gains, underscoring a pattern where strong news has not consistently driven short-term upside.

Key Terms

bispecific antibody, monoclonal antibodies, targeted protein degradation

3 terms

bispecific antibody medical

"a first-in-class bispecific antibody degrader targeting EGFR."

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

monoclonal antibodies medical

"In contrast to conventional monoclonal antibodies that rely on functional inhibition,"

Monoclonal antibodies are lab-made proteins designed to bind a single, specific target on cells or viruses, like identical keys cut to fit one lock. They are used as medicines, tests, or targeted delivery tools and can precisely block or mark disease processes. Investors care because they can become high-value drugs with large sales, long patent protection, and binary risks tied to clinical trial results, regulatory approval, manufacturing scale and pricing.

targeted protein degradation medical

"pioneering next-generation targeted protein degradation approaches for cancer"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Option exercise triggers $25M payment to Pinetree.

CAMBRIDGE, Mass., April 29, 2026 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree"), a biotechnology company pioneering next-generation targeted protein degradation approaches for cancer and other serious diseases, today announced that AstraZeneca (LSE/STO/NYSE: AZN) has exercised its option under the companies' previously announced agreement to obtain an exclusive global license to develop and commercialize PTX-299, a first-in-class bispecific antibody degrader targeting EGFR.

The option exercise follows encouraging preclinical progress and represents an important milestone in the collaboration between the two companies. Under the terms of the agreement, AstraZeneca will assume responsibility for global development and commercialization of the therapeutic candidate.

"This milestone marks an important validation of our AbReptor™ platform," said Hojuhn Song, Ph.D., Founder and CEO of Pinetree Therapeutics. "We are pleased that AstraZeneca has exercised its option to advance PTX-299, and we look forward to seeing them continue the development of this promising therapeutic candidate. By combining Pinetree's breakthrough protein degradation platform with AstraZeneca's global expertise in cancer drug development, we believe that PTX-299 has the potential to bring a meaningful new treatment option to patients with EGFR-driven cancers."

EGFR plays a critical role in the growth and survival of cells in multiple tumor types. While EGFR-targeted therapies have transformed patient outcomes, resistance can develop, highlighting the need for new therapeutic strategies. By leveraging Pinetree's antibody-based protein degradation technology, PTX-299 is designed to selectively eliminate disease-driving EGFR proteins rather than simply inhibiting their activity, potentially overcoming key resistance mechanisms.

The therapeutic candidate was developed using AbReptor™, Pinetree's proprietary multispecific antibody-based targeted protein degradation platform. In contrast to conventional monoclonal antibodies that rely on functional inhibition, AbReptor™ drives the active removal of disease-associated proteins through targeted degradation. By enabling the elimination of membrane-bound and extracellular targets, this platform extends beyond the limitations of traditional inhibition-based antibody therapies.

Under the terms of the agreement, AstraZeneca's exercise of the option triggers a $25 million option closing payment to Pinetree. Pinetree is also eligible to receive potential future development, regulatory, and commercial milestone payments and tiered royalties on global net sales if the product is successfully developed and commercialized. The total potential value of the agreement exceeds $500 million.

About Pinetree Therapeutics
Pinetree Therapeutics, based in Cambridge, MA, is a preclinical-stage biotech company developing next-generation targeted protein degraders (TPDs) to overcome drug resistance and tumor recurrence in oncology, with applications in inflammation and immunology. Its proprietary AbReptor™ platform enables selective degradation of membrane-bound and extracellular proteins, offering a differentiated mechanism of action and durable therapeutic benefit. Pinetree is also advancing trispecific degraders and ADC-integrated platforms.

For more information, visit https://www.pinetreetx.com/.

Contact:
Zachary Park
pr@pinetreetx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/pinetree-therapeutics-announces-exercise-of-option-to-license-egfr-degrader-program-by-astrazeneca-302754627.html

SOURCE PineTree Therapeutics

FAQ

What payment did Pinetree receive when AstraZeneca exercised the PTX-299 option (AZN)?

Pinetree received a $25 million option-closing payment upon exercise. According to Pinetree, the payment is the immediate consideration and additional future milestone and royalty payments are possible if development and commercialization succeed.

Who will develop and commercialize PTX-299 after AstraZeneca exercised the option (AZN)?

AstraZeneca will assume responsibility for global development and commercialization of PTX-299. According to Pinetree, AstraZeneca now leads clinical development, regulatory strategy, and worldwide commercialization efforts for the candidate.

What is the total potential value of the Pinetree–AstraZeneca PTX-299 agreement (AZN)?

The agreement’s total potential value exceeds $500 million, including milestones and royalties. According to Pinetree, that figure combines potential development, regulatory, commercial milestones and tiered royalties on global net sales.

How does PTX-299’s mechanism differ from conventional EGFR therapies in the AstraZeneca deal (AZN)?

PTX-299 is designed to selectively degrade EGFR proteins rather than merely inhibit them. According to Pinetree, the AbReptor platform enables targeted removal of membrane-bound and extracellular proteins, potentially addressing resistance mechanisms to inhibition-based therapies.

Will Pinetree retain any financial upside from PTX-299 after AstraZeneca’s option exercise (AZN)?

Yes. Pinetree is eligible for future development, regulatory, and commercial milestone payments plus tiered royalties on global net sales. According to Pinetree, these contingent payments provide ongoing financial participation if the product is successfully commercialized.

Does AstraZeneca’s exercise of the PTX-299 option change Pinetree’s role in development (AZN)?

Yes. AstraZeneca now leads development and commercialization while Pinetree retains rights to milestone and royalty payments. According to Pinetree, management of global clinical and regulatory programs transfers to AstraZeneca under the license terms.